Validation study of retrospective recall of disease-targeted function: Results from the prostate cancer outcomes study

Medical Care

Volumn 38, Issue 8, 2000, Pages 847-857

  Legler, J ^a   Potosky, A L ^a   Gilliland, F D ^b   Eley, J W ^c   Stanford, J L ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c EMORY UNIVERSITY   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Prostate cancer; Quality of life; Retrospective recall; Validation

Indexed keywords

AGED; ARTICLE; ATTITUDE TO HEALTH; CANCER REGISTRY; COMPARATIVE STUDY; HUMAN; MALE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROSTATE TUMOR; QUALITY OF LIFE; RECALL; REPRODUCIBILITY; STATISTICAL MODEL;

AGED; ATTITUDE TO HEALTH; HUMANS; LINEAR MODELS; MALE; MENTAL RECALL; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATIC NEOPLASMS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SEER PROGRAM;

EID: 0034244275     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-200008000-00008     Document Type: Article

References (25)

1. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-954.
2. Kramer BS, Brown ML, Prorok PC, Potosky Al, Gohagan JK. Prostate cancer screening: What we know and what we need to know. Ann Intern Med 1993;119:914-923.
3. Collins MN, Barry MJ. Controversies in prostate cancer screening: Analogies to the early lung cancer screening debate. JAMA 1996;276:1976-1979.
4. Whitmore WF Jr. Management of clinically localized prostate cancer: An unresolved problem. JAMA 1993;269:2676-2677.
5. National Cancer Institute. NCI monograph: Consensus development conference on the management of clinically localized prostate cancer. 7th ed. Washington, DC: US Govt Printing Office, 1988. Publication No. 88-3005.
6. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer: A decision analytic view. JAMA 1994;272:773-780.
7. Fleming C, Wasson J, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993;269:2650-2658.
8. Coley CM, Barry MJ, Fleming C, Fahs MC, Mulley AG. Early detection of prostate cancer, part II: Estimating the risks, benefits, and costs: American College of Physicians [see comments]. Ann Intern Med 1997;126:468-479.
9. Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, et al. Patient-reported symptoms after primary therapy for early prostate cancer: Results of a prospective cohort study. J Clin Oncol 1998;16:275-283.
10. Pedersen KV, Carlsson P, Rahmquist M, Varenhorst E. Quality of life after radical retropubic prostatectomy for carcinoma of the prostate. Eur Urol 1993;24:7-11.
11. Walsh PC, Epstein JI, Lowe FC. Potency following radical prostatectomy with wide unilateral excision of the neurovascular bundle. J Urol 1987;138:823-827.
12. Catalona WJ, Basler JW. Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy. J Urol 1993;150:905-907.
13. Fowler FJ Jr, Barry MJ, Lu-Yao GL, Roman A, Wasson JH, Wennberg JE. Patient-reported complications and follow-up treatment following radical prostatectomy: The national Medicare experience (1988-1990). Urology 1993;42:622-629.
14. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995;273:129-135.
15. Potosky AL, Harlan LC, Stanford JL, Gilliland FD, Hamilton AS, Albertsen PC, et al. Prostate cancer practice patterns and quality of life: The Prostate Cancer Outcomes Study. J Natl Cancer Inst 1999;91:1719-1724.
16. Aseltine RH Jr, Carlson KJ, Fowler FJ Jr, Barry MJ. Comparing prospective and retrospective measures of treatment outcomes. Med Care 1995;33:AS67-AS76.
17. Fleiss JL. The design and analysis of clinical experiments. New York: John Wiley & Sons; 1986.
18. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174.
19. McCullagh P, Nelder JA Generalized linear models. New York: Chapman & Hall; 1983.
20. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
21. Byrt T, Bishop J, Carlin JB. Bias, prevalence and kappa. J Clin Epidemiol 1993;46:423-429.
22. Litwin MS, McGuigan KA. Accuracy of recall in health-related quality-of-life assessment among men treated for prostate cancer. J Clin Oncol 1999;17:2882-2888.
23. Guyatt GH, Berman LB, Townsend M, Taylor DW. Should study subjects see their previous responses? J Chronic Dis 1985;38:1003-1007.
24. Howard GS, Ralph KM, Gulanick NA, Maxwell SE, Nance SW, Gerber SK. Internal invalidity in pretest-posttest self-report evaluations and a reevaluation of retrospective pretests. Appl Psychol Meas 1979;3:1-23.
25. Sprangers MA. Response-shift bias: A challenge to the assessment of patients' quality of life in cancer clinical trials. Cancer Treat Rev 1996;22(suppl A):55-62.